Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Treasury Shares (2016 - 2025)

Regenxbio (RGNX) has 9 years of Treasury Shares data on record, last reported at $2.8 million in Q4 2025.

  • For Q4 2025, Treasury Shares rose 39.57% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $2.8 million, up 39.57%, while the annual FY2025 figure was $2.8 million, 39.57% up from the prior year.
  • Treasury Shares reached $2.8 million in Q4 2025 per RGNX's latest filing, down from $2.9 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $3.0 million in Q2 2025 and bottomed at $254000.0 in Q1 2021.
  • Average Treasury Shares over 5 years is $1.4 million, with a median of $1.4 million recorded in 2023.
  • Peak YoY movement for Treasury Shares: soared 200.42% in 2023, then increased 17.13% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $277000.0 in 2021, then soared by 121.3% to $613000.0 in 2022, then surged by 113.54% to $1.3 million in 2023, then surged by 56.0% to $2.0 million in 2024, then soared by 39.57% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $2.8 million in Q4 2025, $2.9 million in Q3 2025, and $3.0 million in Q2 2025.